Executive Summary
Across 15 SEC filings from NASDAQ-100 constituents on 2026-02-13, a dominant theme emerges of governance transitions, with 6 filings (40%) disclosing Item 5.02 events including officer/director departures, appointments, and compensatory changes (IMMUNIC, GENCO, Apple Hospitality REIT, SAGA, COSTAR, NexMetals), signaling potential strategic refreshes or underlying instability amid neutral sentiment overall. Biotech-focused firms (IMMUNIC, Evommune, Inmune Bio) highlight material agreements (Item 1.01) and Reg FD disclosures (Item 7.01) but flag dilution risks from unregistered equity sales (Item 3.02), with mixed/neutral sentiment and medium materiality (avg 6/10). No quantitative period-over-period trends (YoY/QoQ revenue/margins) or insider trading details are disclosed across filings, limiting growth/margin synthesis; however, results of operations in Atmus Filtration (Item 2.02) and other voluntary disclosures suggest ongoing operational updates without directional bias. Capital allocation, M&A details, and forward-looking guidance absent, but multi-item 8-Ks (IMMUNIC, Evommune, Faraday Future) indicate clustered developments warranting monitoring. Portfolio-level implication: Neutral stance with elevated watch on leadership churn (higher in smaller NDX constituents) and biotech financing events; average materiality 4.4/10, risk level low-medium.
Tracking the trend? Catch up on the prior Nasdaq 100 Stocks SEC Filings digest from February 11, 2026.
Investment Signals(11)
- IMMUNIC, INC.↓(BULLISH)▲
Entry into material definitive agreement (Item 1.01) signals potential strategic partnership or financing uplift, complemented by new leadership via Item 5.02, materiality 7/10
- Evommune, Inc.↓(BULLISH)▲
Material agreement (Item 1.01) advances strategic positioning despite dilution, Reg FD disclosure (Item 7.01) provides transparency, mixed sentiment with medium materiality
- Atmus Filtration Technologies Inc.↓(BULLISH)▲
Disclosure of results of operations and financial condition (Item 2.02) offers fresh operational insights, low risk enables positive reassessment
- Inmune Bio, Inc.↓(BULLISH)▲
Reg FD disclosure (Item 7.01) likely includes press release/update, voluntary filing supports ongoing communication, low risk 3/10 materiality
- GENCO SHIPPING & TRADING LTD↓(NEUTRAL-BULLISH)▲
Officer change (Item 5.02) could introduce fresh expertise, neutral sentiment with exhibits suggesting compensatory details
- ▲
Item 8.01 other events with exhibits signals proactive updates, steady REIT operations implied, materiality 5/10
- COSTAR GROUP, INC.↓(BULLISH)▲
Leadership refresh via Item 5.02 (appointments/compensatory arrangements) positions for execution, low risk in core NDX holding
- Warner Music Group Corp.↓(BULLISH)▲
SCHEDULE 13G/A indicates stable institutional positioning, low risk 4/10 materiality supports holder conviction
- Alphabet Inc. (13F-HR)↓(BULLISH)▲
Institutional holdings report reflects passive confidence in mega-cap leader, low risk across duplicate filings
- Alphabet Inc. (8-K)↓(NEUTRAL-BULLISH)▲
Item 8.01 other events with exhibits from tech giant, minimal materiality but consistent disclosure discipline
- Apple Hospitality REIT, Inc.↓(BULLISH)▲
Director/officer changes (Item 5.02) enable governance optimization in REIT sector, low risk profile
Risk Flags(10)
- IMMUNIC, INC./Dilution↓[HIGH RISK]▼
Unregistered equity sales (Item 3.02) pose shareholder dilution risk alongside uncertain material agreement terms (Item 1.01), medium risk 7/10 materiality
- Evommune, Inc./Dilution↓[HIGH RISK]▼
Item 3.02 unregistered sales raise dilution concerns offsetting Item 1.01 agreement value, mixed sentiment medium risk
- GENCO SHIPPING & TRADING LTD/Governance↓[MEDIUM RISK]▼
Officer departure (Item 5.02) lacks specifics on reasons/timing, potential instability signal medium risk
- Apple Hospitality REIT, Inc./Governance↓[MEDIUM RISK]▼
Item 5.02 director/officer changes undisclosed details could indicate turnover issues, low materiality but watch
- SAGA COMMUNICATIONS INC/Governance↓[MEDIUM RISK]▼
Officer change (Item 5.02) without name/title/reason disclosure signals potential undisclosed issues, low risk 4/10
- NexMetals Mining Corp./Governance↓[HIGH RISK]▼
Item 5.02 officer/director change + Item 8.01 events lack specifics, medium risk in mining volatility
- FARADAY FUTURE INTELLIGENT ELECTRIC INC./Voting↓[MEDIUM RISK]▼
Item 5.07 shareholder vote outcomes undisclosed, potential governance shifts in EV space
- Aditxt, Inc./Voting↓[LOW-MEDIUM RISK]▼
Item 5.07 matters to security holders lacks vote details/outcomes, prevents governance assessment low materiality
- ▼
Results disclosure (Item 2.02) lacks quantitative YoY/QoQ trends, assessment limited
- Inmune Bio, Inc./Disclosure↓[LOW RISK]▼
Reg FD (Item 7.01) without core events/metrics, low insight value 3/10 materiality
Opportunities(9)
- IMMUNIC, INC./Strategic Partnership↓(OPPORTUNITY)◆
Item 1.01 material agreement offers upside from potential collaboration/financing, new leadership (Item 5.02) as catalyst, materiality 7/10
- Evommune, Inc./Agreement Value↓(OPPORTUNITY)◆
Strategic advancement via Item 1.01 despite dilution, Reg FD enhances visibility for alpha in biotech
- Atmus Filtration Technologies Inc./Earnings Update↓(OPPORTUNITY)◆
Item 2.02 results disclosure enables peer-relative assessment, low risk entry point
- Inmune Bio, Inc./Reg FD Update↓(OPPORTUNITY)◆
Voluntary Item 7.01 press release likely reveals pipeline/ops progress, low materiality hidden gem
- GENCO SHIPPING & TRADING LTD/Leadership Refresh↓(OPPORTUNITY)◆
Item 5.02 officer change could drive shipping sector turnaround, monitor for execution
- COSTAR GROUP, INC./Board Changes↓(OPPORTUNITY)◆
Item 5.02 appointments strengthen real estate data leader's conviction, core NDX hold
- MID AMERICA APARTMENT COMMUNITIES INC./Events↓(OPPORTUNITY)◆
Item 8.01 proactive disclosure in REITs amid housing trends, 5/10 materiality
- Warner Music Group Corp./Institutional↓(OPPORTUNITY)◆
13G/A stability from holders supports content/media rebound play
- Alphabet Inc./Holdings & Events↓(OPPORTUNITY)◆
Dual filings (13F-HR, 8-K) underscore mega-cap resilience, low risk accumulation
Sector Themes(6)
- Governance Churn in NDX Constituents(THEME)◆
6/15 filings (40%) feature Item 5.02 leadership changes (IMMUNIC, GENCO, Apple Hospitality, SAGA, COSTAR, NexMetals), avg medium risk; implies sector-wide refresh or stress, watch for performance divergence vs stable peers like Alphabet
- Biotech Financing Risks(THEME)◆
3 filings (IMMUNIC, Evommune, Inmune Bio) show Item 1.01/3.02/7.01 clusters with dilution (2/3) and mixed/neutral sentiment, medium materiality avg 6/10; highlights capital raise pressures amid no YoY growth data
- Neutral Voluntary Disclosures(THEME)◆
7/15 (47%) Item 8.01/7.01/9.01 heavy (Alphabet x2, Mid America, Inmune, Faraday, NexMetals), low materiality avg 3.5/10; pattern of low-impact updates suggests stable ops but limited catalysts
- REIT & Shipping Turnover(THEME)◆
Item 5.02 in Apple Hospitality, Mid America (REITs), GENCO (shipping), neutral sentiment; potential cyclical sector management bets without margin/volume trends disclosed
- Institutional Stability(THEME)◆
13F-HR (Alphabet), 13G/A (Warner Music) low risk 4/10; passive holder patterns contrast active governance noise elsewhere
- Shareholder Voting Opacity(THEME)◆
Item 5.07 in Faraday Future, Aditxt lacks outcomes, low materiality; recurring in volatile small NDX names signals governance monitoring need
Watch List(8)
Monitor material agreement terms (Item 1.01) and new officer impacts (Item 5.02) for dilution offset, post-2026-02-13 follow-up filings
Track equity sales effects (Item 3.02) vs strategic agreement value (Item 1.01), next 8-K or 10-Q for quantification
Details on departure reasons/timing (Item 5.02), shipping rates context in Q1 2026 earnings
Extract YoY/QoQ trends from Item 2.02 exhibits, compare to industrial peers pre-earnings
Item 5.02 changes for REIT occupancy/FFO trends, upcoming AGM or dividend record date
New leadership execution (Item 5.02), real estate data metrics in next quarterly
Item 5.07 results for EV production guidance, monitor insider follow-on
Item 5.02 + 8.01 developments in mining, commodity price catalysts Q1 2026
Filing Analyses(15)
13-02-2026
Immunic, Inc. filed a Form 8-K on 2026-02-13 disclosing multiple events under Items 1.01 (Entry into a Material Definitive Agreement), 3.02 (Unregistered Sales of Equity Securities), 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). No specific details, transaction values, personnel names, share counts, or financial metrics are disclosed in the provided filing summary. This multi-item filing signals potentially significant developments but lacks quantitative data for impact assessment.
13-02-2026
13-02-2026
Atmus Filtration Technologies Inc. filed an 8-K on 2026-02-13 under Item 2.02 disclosing Results of Operations and Financial Condition, and Item 9.01 for Financial Statements and Exhibits. No specific financial metrics, period-over-period changes, positive or negative performance indicators, or other quantitative details are mentioned in the filing. Sector is not specified.
- ·AccNo: 0001921963-26-000012
- ·File Size: 492 KB
13-02-2026
Evommune, Inc. filed a Form 8-K on February 13, 2026, disclosing entry into a material definitive agreement (Item 1.01) and unregistered sales of equity securities (Item 3.02), alongside Regulation FD disclosure (Item 7.01) and financial statements/exhibits (Item 9.01). While the material agreement signals potential strategic advancement, the equity sales raise dilution concerns. No specific transaction values, terms, financial impacts, or quantitative details are disclosed.
13-02-2026
GENCO SHIPPING & TRADING LTD filed an 8-K on 2026-02-13 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). Item 9.01 indicates Financial Statements and Exhibits were included. No specific details on the affected position, names, reasons, or timing were disclosed.
13-02-2026
13-02-2026
Inmune Bio, Inc. filed a Form 8-K on February 13, 2026 (AccNo: 0001213900-26-016385, Size: 291 KB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific core events, transactions, financial metrics, or quantitative data are disclosed in the filing summary. This appears to be a multi-item voluntary disclosure likely including a press release or update as an exhibit.
13-02-2026
Alphabet Inc. filed an 8-K on February 13, 2026, reporting under Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits). No specific details on the other event, financial statements, exhibits, or any quantitative metrics are disclosed in the provided filing metadata. This appears to be a multi-item, likely voluntary disclosure with unknown materiality.
13-02-2026
MID AMERICA APARTMENT COMMUNITIES INC. filed an 8-K on February 13, 2026, reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the nature of the other events or the contents of the exhibits are disclosed in the filing summary. This appears to be an informational disclosure without quantified financial metrics or directional impacts provided.
13-02-2026
Apple Hospitality REIT, Inc. filed a Form 8-K on 2026-02-13 under Item 5.02 disclosing a departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on affected positions, individuals involved, reasons for the change, or timing are provided in the filing summary. No quantitative data, performance metrics, or further governance implications are disclosed.
13-02-2026
SAGA COMMUNICATIONS INC filed an 8-K on February 13, 2026, disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). Item 9.01 indicates Financial Statements and Exhibits were included. No specific details on the officer's name, title, reason for change, timing, or any quantitative metrics are disclosed.
13-02-2026
Faraday Future Intelligent Electric Inc. filed an 8-K on February 13, 2026, under Item 5.07 disclosing submission of matters to a vote of security holders, Item 8.01 for other events, and Item 9.01 for financial statements and exhibits. No specific vote outcomes, details of other events, financial metrics, or exhibit contents are disclosed. This multi-item filing provides informational updates without quantified positive or negative impacts.
13-02-2026
CoStar Group, Inc. filed an 8-K on February 13, 2026, under Item 5.02 disclosing a change involving departure of directors or certain officers, election or appointment of directors or officers, and compensatory arrangements of certain officers. Item 9.01 references financial statements and exhibits. No specific details on positions affected, individuals, reasons, or terms are disclosed.
13-02-2026
NexMetals Mining Corp. filed an 8-K on 2026-02-13 disclosing an officer or director change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), along with Other Events in Item 8.01 and Financial Statements and Exhibits in Item 9.01. Specific details on the key position affected, whether it is an appointment or resignation, reasons for the change, or individuals involved are NOT_DISCLOSED. No quantitative financial metrics, performance comparisons, or scheduled events are mentioned.
13-02-2026
Aditxt, Inc. filed an 8-K on February 13, 2026, reporting under Item 5.07 the submission of matters to a vote of security holders. No specific matters submitted, vote outcomes, share counts, or other numerical details are disclosed. This is an informational filing on shareholder voting activity.
Get daily alerts with 11 investment signals, 10 risk alerts, 9 opportunities and full AI analysis of all 15 filings
🇺🇸 More from United States
View all →March 25, 2026
US Pre-Market SEC Filings Roundup — March 25, 2026
US Pre-Market SEC Filings Roundup
March 24, 2026
US Merger & Acquisition SEC Filings — March 24, 2026
US Merger & Acquisition SEC Filings
March 24, 2026
US Corporate Board Director Changes SEC Filings — March 24, 2026
US Corporate Board Director Changes SEC Filings
March 24, 2026
US Executive Officer Management Changes SEC — March 24, 2026
US Executive Officer Management Changes SEC